International
Available Domestic
International
Available Domestic
Dragon Pharma
Dragon Pharma BPC-157 5 mg and TB-500 5 mg Repair Blend Vial
Injection · 5 mg + 5 mg/ ml · vial
In stock · ships within 24h
Out of stock
$80.00
Dragon Pharma BPC-157 5 mg and TB-500 5 mg is a two-peptide repair blend supplied as one lyophilised vial holding 5 mg of each peptide. It saves a second reconstitution when both repair-pathway peptides belong to the same laboratory protocol.
Each vial is GMP-manufactured and HPLC-verified, with a Certificate of Analysis on file. Reconstitute with bacteriostatic water. The blend is for sale with U.S. and international shipping.
Shipping
Not available in this combination
Discreet plain packaging
Worldwide reship guarantee
Crypto & card accepted
Product overview
Dragon Pharma BPC-157 and TB-500 Blend - Two-Peptide Repair Vial
Dragon Pharma BPC-157 5 mg and TB-500 5 mg puts both repair-pathway peptides in one vial, 5 mg of each. BPC-157 is the pentadecapeptide studied in tendon and gut models, and TB-500 is the thymosin beta-4 fragment studied for cell migration, so one reconstitution covers both routes. Neither peptide has a licensed product or a human dose. The blend is for sale from a GMP manufacturer with batch testing and a Certificate of Analysis on file.
- BPC-157 5 mg plus TB-500 5 mg - 10 mg of peptide per vial
- Two repair-pathway peptides, one reconstitution step
- No half-life established for either peptide in the sources checked
- GMP-manufactured, HPLC-verified, COA on file per batch
How the Two-Peptide Blend Works
BPC-157 is described in models of angiogenesis, fibroblast activity and mucosal repair, while TB-500 is a thymosin beta-4 fragment acting through actin regulation, which affects cell migration and remodelling. Because the vials are combined before dilution, the solution holds a fixed ratio, so the amounts drawn for each peptide move together. That is the main practical difference from buying BPC 157 and TB 500 as separate vials.
Research Amounts and Handling
No human dose exists for either peptide, so every figure is research practice. Reported work uses 150 to 375 mcg of BPC-157 twice daily, and a TB-500 loading phase of about 2.5 mg twice weekly for four to six weeks followed by 2.5 mg per week; in a fixed 5 mg plus 5 mg blend those amounts move together. Reconstitute with bacteriostatic water: 2 ml gives 2.5 mg per ml of each peptide, so a 2.5 mg TB-500 amount measures 1 ml and a 250 mcg BPC-157 amount measures 0.1 ml.
Quality & Authenticity
Every batch is produced under GMP conditions and checked by independent HPLC, with the Certificate of Analysis held for the batch, which matters more in a blend, where both components must be present at the stated amounts. Pain and redness at the injection site are the usual local reports and there are no long-term human safety data for the combination. Both peptides are named in the WADA prohibited list, so the blend is not usable in any tested setting. The Zyvex line lists BPC-157 and TB 500 as separate products.
For laboratory research only. Consult a healthcare professional before use.
Specifications
| Trade Name | BPC-157 5 mg / TB-500 5 mg (Blend) |
| Generic Name | BPC-157 plus TB-500 (thymosin beta-4 fragment) |
| Manufacturer | Dragon Pharma |
| Dosage | 5 mg of each peptide per vial, 10 mg total |
| Package | 1 lyophilised vial for reconstitution |
| Drug Class | Research peptide blend (two repair-pathway peptides) |
| Administration | Reconstitute with bacteriostatic water, subcutaneous injection |
| Reference Half-Life | Not established for either peptide in the sources checked |
| Shipping | International and U.S. domestic options |
Stacks
Consult a healthcare professional before any cycle. Doses are common community protocols.
FAQ
Before you ask
Questions, answered
One lyophilised vial holds 5 mg of BPC-157 and 5 mg of TB-500, 10 mg of peptide in total. BPC-157 is a pentadecapeptide studied in tendon and gut repair models, and TB-500 is a fragment of thymosin beta-4 studied for cell migration. Neither peptide has a licensed product or a human dose, so the blend is a laboratory material.
BPC-157 and TB-500 are studied through different mechanisms: BPC-157 in models of angiogenesis, fibroblast activity and mucosal repair, and TB-500 through actin regulation, which affects cell migration and tissue remodelling. Blending them puts both routes in one solution. The trade-off is that the ratio is fixed once reconstituted, so the amount of one peptide cannot be changed without changing the other.
No human dose exists for either peptide. Reported work uses 150 to 375 mcg of BPC-157 twice daily, and a TB-500 loading phase of about 2.5 mg twice weekly for four to six weeks followed by 2.5 mg per week. In a fixed 5 mg plus 5 mg blend those amounts move together. Reconstituting with 2 ml of bacteriostatic water gives 2.5 mg per ml of each peptide.
Pain, redness and irritation at the injection site are the usual local reports, and hypersensitivity reactions to the peptides have been described. Because the peptides are combined before dilution, any reaction cannot be attributed to one component in isolation. No long-term human safety data exist, and both peptides are named in the WADA prohibited list.
Yes. The 5 mg plus 5 mg vial is listed on this page with international and U.S. domestic shipping options, and the price charged matches the option you select. Orders are dispatched after payment confirmation. The product is sold strictly for laboratory research and is not a licensed medicine in any country.
No reviews yet
Be the first to share your experience with Dragon Pharma BPC-157 5 mg and TB-500 5 mg Repair Blend Vial
Log in to write a reviewComplete the cycle
Stack it with
International
Available Domestic
International
International
Available Domestic